201 related articles for article (PubMed ID: 28917642)
21. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
22. Establishment of a DNA-free genome editing and protoplast regeneration method in cultivated tomato (Solanum lycopersicum).
Liu Y; Andersson M; Granell A; Cardi T; Hofvander P; Nicolia A
Plant Cell Rep; 2022 Sep; 41(9):1843-1852. PubMed ID: 35773498
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas9 Genome Editing vs. Over-Expression for Fluorescent Extracellular Vesicle-Labeling: A Quantitative Analysis.
Strohmeier K; Hofmann M; Hauser F; Sivun D; Puthukodan S; Karner A; Sandner G; Le Renard PE; Jacak J; Mairhofer M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008709
[TBL] [Abstract][Full Text] [Related]
25. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
[TBL] [Abstract][Full Text] [Related]
26. CRISPR/Cas9-Based Genome Editing Using Rice Zygotes.
Toda E; Okamoto T
Curr Protoc Plant Biol; 2020 Jun; 5(2):e20111. PubMed ID: 32515907
[TBL] [Abstract][Full Text] [Related]
27. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
28. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
Tapscott T; Guarnieri MT; Henard CA
Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
[TBL] [Abstract][Full Text] [Related]
29. Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina.
Yang TC; Chang CY; Yarmishyn AA; Mao YS; Yang YP; Wang ML; Hsu CC; Yang HY; Hwang DK; Chen SJ; Tsai ML; Lai YH; Tzeng Y; Chang CC; Chiou SH
Acta Biomater; 2020 Jan; 101():484-494. PubMed ID: 31672582
[TBL] [Abstract][Full Text] [Related]
30. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
31. Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes.
Jain PK; Lo JH; Rananaware S; Downing M; Panda A; Tai M; Raghavan S; Fleming HE; Bhatia SN
Nanoscale; 2019 Nov; 11(44):21317-21323. PubMed ID: 31670340
[TBL] [Abstract][Full Text] [Related]
32. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Verma R; Sahu R; Singh DD; Egbo TE
Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
[TBL] [Abstract][Full Text] [Related]
33. Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
Chae SY; Jeong E; Kang S; Yim Y; Kim JS; Min DH
J Control Release; 2022 May; 345():108-119. PubMed ID: 35247491
[TBL] [Abstract][Full Text] [Related]
34. Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery.
Wang Y; Ma B; Abdeen AA; Chen G; Xie R; Saha K; Gong S
ACS Appl Mater Interfaces; 2018 Sep; 10(38):31915-31927. PubMed ID: 30222305
[TBL] [Abstract][Full Text] [Related]
35. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9-mediated genome editing in a reef-building coral.
Cleves PA; Strader ME; Bay LK; Pringle JR; Matz MV
Proc Natl Acad Sci U S A; 2018 May; 115(20):5235-5240. PubMed ID: 29695630
[TBL] [Abstract][Full Text] [Related]
37. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
[TBL] [Abstract][Full Text] [Related]
38. Expanding the scope of CRISPR/Cas9-mediated genome editing in plants using an xCas9 and Cas9-NG hybrid.
Niu Q; Wu S; Li Y; Yang X; Liu P; Xu Y; Lang Z
J Integr Plant Biol; 2020 Apr; 62(4):398-402. PubMed ID: 31702097
[TBL] [Abstract][Full Text] [Related]
39. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
40. CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool.
Sahel DK; Mittal A; Chitkara D
J Pharmacol Exp Ther; 2019 Sep; 370(3):725-735. PubMed ID: 31122933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
